Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome

Leukemia and Lymphoma

Volumn 45, Issue 2, 2004, Pages 301-308

  Salih, Helmut R ^a   Nuessler, Volkmar ^b   Denzlinger, Claudio ^a   Starling, Gary C ^c   Kiener, Peter A ^c   Schmetzer, Helga M ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

4 1BB ligand; CD137 ligand; CD178 Fas ligand; Myelodysplastic syndrome; Prognostic factor

Indexed keywords

CD137 ANTIGEN; FAS LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; BLOOD LEVEL; BONE MARROW CELL; CELL COUNT; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPENIA; DISEASE COURSE; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNOLOGICAL PARAMETERS; KARYOTYPING; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; SCORING SYSTEM; SEROLOGY; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD137; DISEASE PROGRESSION; FAS LIGAND PROTEIN; FEMALE; HUMANS; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS;

EID: 0842279754     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001602372     Document Type: Article

References (26)

1. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Gallon, D.A.G., Gralnick, H.R., et al. (1982) "The French-American-British Co-operative Group: proposals for the classification of the myelodysplastic syndromes", British Journal of Haematology, 51, 189-199.
2. Foucar, K., Langdon, R.M., Armitage, J.O., Olson, D.B. and Caroll, T.J. (1985) "Myelodysplastic syndromes. A clinical and pathological analysis of 109 cases", Cancer, 56, 553-561.
3. Mufti, G.J., Stevens, J.R., Oscier, D.G., Hamblin, T.J. and Machin, D. (1985) "Myelodysplastic syndromes: A scoring system with prognostic significance", British Journal of Haematology, 59, 425-433.
4. Weisdorf, D.J., Oken, M.M., Johnson, G.J., and Rydell, R.E. (1983) "Chronic myelodysplastic syndrome: Short survival with or without evolution to acute leukaemia", British Journal of Haematology, 55, 691-700.
5. Greenberg, P.L., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., et al. (1997) "International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes", Blood, 89, 2079-2088.
6. Kato, K., Santana-Sahagun, E., Rassenti, L.Z., Weisman, M.H., Tamura, N., Kobayashi, S., et al. (1999) "The soluble CD40 ligand sCD154 in systemic lupus erythematosus", Journal of Clinical Investigation, 104, 947-955.
7. Jodo, S., Kobayashi, S., Kayagaki, N., Ogura, N., Feng, Y., Amasaki, Y., et al. (1997) "Serum levels of soluble Fas/APO-1 (CD95 and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases", Clinical and Experimental Immunology, 107, 89-95.
8. Molica, S., Vitelli, G., Levato, D., Crispino, G., Dell'Olio, M., Dattilo, A., et al. (1998) "CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily", Haematologica, 83, 398-402.
9. Salih, H.R., Schmetzer, H.M., Burke, C., Starling, G.C., Dunn, R., Pelka-Fleischer, R., et al. (2001) "Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies", Journal Immunology, 167, 4059-4066.
10. Gersuk, G.M., Beckham, C., Loken, M.R., Kiener, P., Anderson, J.E., Farrand, A., et al. (1998) "A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome", British Journal of Haematology, 103, 176-188.
11. Mativi, B.Y., Mundle, S., Ali, A., Bag, K., Venugopal, P., Feldman, G., et al. (1997) "Fas/CD178 system could be one of the mediators of excessive apoptosis in myelodysplastic syndromes", Blood, 90 (Suppl 1), 202.
12. Gupta, P., Niehans, G.A., LeRoy, S.C., Gupta, K., Morrison, V.A., Schultz, C., et al. (1999) "Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival", Leukemia, 13, 44-53.
13. Trauth, B.C., Klas, C., Peters, A.M., Matzku, S., Moller, P., Falk, W., et al. (1989) "Monoclonal antibody-mediated tumor regression by induction of apoptosis", Science, 245, 301-305.
14. Igney, F.H., Behrens, C.K. and Krammer, P.H. (2000) "Tumor counterattack-concept and reality", European Journal of Immunology, 30, 725-731.
15. Salih, H.R., Kosowski, S.G., Haluska, V.F., Starling, G.C., Loo, D.T., Lee, F., et al. (2000) "Constitutive expression of functional 4-1BB (CD 137) ligand on carcinoma cells", Journal of Immunology, 165, 2903-2910.
16. Cannons, J.L., Lau, P., Ghumman, B., DeBenedette, M.A., Yagita, H., Okumura, K., et al. (2001) "4-1BB Ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy", Journal of Immunology, 167, 1313-1324.
17. Claessens, Y.-E., Bouscary, D., Dupont, J.-M., Picard, F., Melle, J., Gisselbrecht, S., et al. (2002) "In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis", Blood, 99, 1594-1601.
18. Tanaka, M., Itai, T., Adachi, M. and Nagata, S. (1998) "Down-regulation of Fas ligand by shedding", Nature Medicine, 4, 31-36.
19. Schneider, P., Holler, N., Bodmer, J.L., Hahne, M., Frei, K., Fontana, A., et al. (1998) "Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of the proapoptotic activity and loss of liver activity", Journal of Experimental Medicine, 187, 1205-1213.
20. Salih, H.R., Starling, G.C., Knauff, M., Davis, P.M., Pitts, W.J., Aruffo, A., et al. (2001) "Retinoic Acid and Vitamin E Modulate Expression and Release of CD178 in Carcinoma Cells: Consequences for Induction of Apoptosis in CD95 Sensitive Cells", Experimental Cell Research, 270, 248-258.
21. Mazumdar, M. and Glassman, J.R. (2000) "Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatments", Statistics Medicine, 19, 113-132.
22. Yoshida, Y. and Mufti, G.J. (1999) "Apoptosis and its significance in MDS: controversies revisited", Leukemia Research, 23, 777-785.
23. Greenberg, P.L. (1998) "Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment", Leukemia Research, 22, 1123-1136.
24. Michel, J., Pauly, S., Langstein, P., Krammer, P.H. and Schwarz, H. (1999) "CD137-induced apoptosis is independent of CD95", Immunology, 98, 42-46.
25. Langstein, J., Michel, J. and Schwarz, H. (1999) "CD137 induces proliferation and endomitosis in monocytes", Blood, 94, 3161-3168.
26. Deeg, H.J., Beckham, C., Loken, M.R., Bryant, E., Lesnikova, M., Shulman, H.M., et al. (2000) "Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome", Leukemia and Lymphoma, 37, 405-414.